Glaucoma is the leading cause of irreversible blindness. The most successful way to prevent vision loss from glaucoma is to lower intraocular pressure with filtration surgery. This surgery shunts fluid out of the eye through a channel created during a trabeculectomy procedure or by a transscleral drainage device placed during Minimally Invasive Glaucoma Surgery (MIGS). […]
“For glaucoma surgery to be maximally successful, anti-scarring therapies must be effective, consistent in dosage as well as fast and very easy to administer. In combination with new glaucoma drainage devices, the RadianceTx Beta Ophthalmic Applicator System could revolutionize the treatment of glaucoma.”
A Tucson-based startup company has raised $1 million of a planned $7 million private-financing round to advance a new radiation treatment to prevent complications from a common surgical treatment for glaucoma. Read more at Tucson.com.
RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Read the article in eyewire.news.
RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three clinical studies conducted by preeminent ophthalmic research teams, beta therapy has […]
